Member Log-in

I forgot my password

Not a Member? Register

New Evidence Shows Investments in Vaccination Produce Even Greater Returns than Previously Thought

This article originally appeared on Gavi’s website

The Decade of Vaccine Economics (DoVE) Project, carried out by the Johns Hopkins Bloomberg School of Public Health’s International Vaccine Access Center (IVAC) for nearly ten years, has computed the return-on-investment for vaccines preventing ten infectious diseases in 94 low- and middle-income countries, including 73 countries that have received support from Gavi, the Vaccine Alliance.

An economic lens demonstrates that immunization program costs are truly investments with tangible returns, just like any other type of investment.

Using a model that factors in treatment costs, lost wages, and productivity losses, we estimate that the costs averted via these immunization programs in 94 countries will amount to US$ 828.5 billion for the next decade. This estimated net benefit is about 20 times larger than the costs forecasted for vaccination programs over the next ten years, from 2021-30.

The ROI estimates are helpful for countries with competing priorities, since social return-on-investments help compare investments in health, such as vaccine programs, with other public social investments such as infrastructure, education, and social safety nets—all of which have different success metrics.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Rotavirus Vaccination is Cost Effective and Saves Lives, New Analysis Finds

In an analysis published in the December issue of The Lancet Global Health, investigators from PATH, the London School of Hygiene & Tropical Medicine, and the US Centers for Disease Control and Prevention, analyzed the potential costs of rotavirus vaccination for 10 successive birth cohorts (from 2018 through 2027) in 73 countries eligible for Gavi support, compared … Continued

Materials from Immunization Economics’ 2019 iHEA Pre-Congress Session Now Available

As part of the 2019 iHEA biennial world congress in Basel, Switzerland, the Immunization Economics Special Interest Group (SIG) organized a pre-congress session on July 13-14. The program, which focused on the generation and use of information surrounding immunization costing, financing, and value of vaccination, included: Featured updates on research findings, methodology, and cases; Concurrent … Continued

Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

This news release was originally published on EurekAlert. Below is an excerpt from the news release. Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than … Continued

Choose a Language